CVRx®, a Minneapolis-based cardiovascular medical device company, is dedicated to the development of proprietary active implantable technology for the treatment of high blood pressure and heart failure.

CVRx's one-of-a-kind product, the Barostim neo™, is currently CE marked in Europe. The organization, requiring quick market access for a successive U.S. heart failure pivotal trial, quickly turned to NAMSA to help accelerate the process. Relying on NAMSA’s clinical and consulting services throughout, CVRx realized both cost efficiencies and time savings as a result of the partnership.

Liz Galle, CVRx’s Vice President of Global Clinical Research, is interviewed about the success of this program.

Visit www.namsa.com or www.cvrx.com for further information.

свернуть